Pharmacokinetics of the antineoplastic drug mitomycin C in regional chemotherapy using the aortic stop flow technique in advanced pancreatic carcinoma

Chemotherapy

Volumn 51, Issue 1, 2005, Pages 1-8

  Meyer, Frank ^a   Ridwelski, Karsten ^b   Gebauer, Thomas ^a   Grote, Reinhard ^c   Martens Lobenhoffer, Jens ^a   Lippert, Hans ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Municipal Hospital   (Germany)

^c Department of Diagnostic Radiology ^*  (Germany)

Author keywords

Aortic stop flow; Mitomycin C; Pancreatic carcinoma; Pharmacokinetics; Regional chemotherapy

Indexed keywords

MITOMYCIN C; ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

ABDOMEN; ADVANCED CANCER; AORTA STOP FLOW TECHNIQUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG RESPONSE; ENTEROCOLITIS; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPOXIA; INFECTION; LEUKOCYTE COUNT; MALE; METASTASIS; NAUSEA; PANCREAS CARCINOMA; PERITONITIS; PRIORITY JOURNAL; REGIONAL PERFUSION; REMISSION; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TISSUE PERFUSION; TREATMENT OUTCOME; VOMITING; ADULT; AGED; BIOAVAILABILITY; LIVER TUMOR; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; REVIEW; SURVIVAL RATE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 21344471391     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084016     Document Type: Article

References (33)

1. Shingleton WW, Reeves JW Jr, Keppel RA, Mahaley S, Taylor IM: Studies on abdominal perfusion for cancer chemotherapy. Ann Surg 1960;151:741-741.
2. Blackshear PJ, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H: A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design. Surg Forum 1970;21:136-137.
3. Itin AB: Regional intra-arterial chemotherapy of cancer of the pancreas (in Russian). Khirurgiia (Mosk) 1972;48:22-25.
4. Aigner KR, Müller H, Bassermann R: Intraarterial chemotherapy with MMC, CDDP and 5-FU for nonresectable pancrteatic cancer - a phase II study. Reg Cancer Treat 1990;3:1-6.
5. Aigner KR, Gailhofer S: Regional chemotherapy for non resectable, locally matastasized pancreatic cancer - four studies including 164 cases. Reg Cancer Treat 1993;(suppl B):1-2.
6. Rosenberg L: Pancreatic cancer: Does octreotide offer any promise? Chemotherapy 2001;47(suppl 2):134-149.
7. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
8. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
9. Lin MH, Chen JS, Chen HH, Su W: A phase II trial of gemcitabine in the treatment of advanced duct and periampullary carcinomas. Chemotherapy 2003;49:154-158.
10. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2C- difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
11. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
12. Oettle H, Pelzer U, Hochmuth K, Diebold T, Langrehr J, Schmidt CA, Arning M, Vogl TJ, Neuhaus P, Huhn D, Riess H: Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs 1999;10:699-704.
13. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW: A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002;94:97-103.
14. Cascinu S, Gasparini G, Catalano V, Silva RR, Pancera G, Morabito A, Giordani P, Gattuso D, Catalano G: A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999;10:1377-1379.
15. Lorenz M, Petrowsky H, Heinrich S, Janshon G, Staib-Sebler E, Poloczek Y, Gog C, Oremek G, Encke A: Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. Eur J Surg Oncol 1998;24:542-547.
16. Li WY, Seah SK, Koda RT: Determination of mitomycin C in human aqueous humor and serum by high-performance liquid chromatography. J Chromatogr 1993;619:148-153.
17. Simon R: How large should a phase II trial of a new drug be? Cancer Treat Rep 1987;71:1079-1085.
18. Mori W, Masuda M, Miyanaga T: Hepatic artery ligation and tumor necrosis in the liver. Surgery 1966;59:359-363.
19. Nilsson LA: Therapeutic hepatic artery ligation in patients with secondary liver tumors. Rev Surg 1966;23:374-376.
20. Averbach AM, Stuart OA, Sugarbaker TA, Stephens AD, Fernandez-Trigo V, Shamsa F, Sugarbaker PH: Intraaortic stop-flow infusion: Pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers. Ann Surg Oncol 1995;2:325-331.
21. Kemeny NE, Ron IG: Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999;26:524-535.
22. Aigner K, Walther H, Tonn JC, Krahl M, Wenzl A, Merker G, Schwemmle K: Die isolierte Leberperfusion mit 5-Fluorouracil (5-FU) beim Menschen. Chirurg 1982;53:571-573.
23. Thompson JF, Liu M, Waugh RC, Watson LD, Sheldon DM, Stephen MS, Storey DW, Kam PCA: A percutaneous aortic 'stop-flow' infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994;7:202-204.
24. Lorenz M, Heinrich S, Staib-Sebler E, Kohne CH, Wils J, Nordlinger B, Encke A: Regional chemotherapy in the treatment of advanced pancreatic cancer - is it relevant? Eur J Cancer 2000;36:957-965.
25. Cantore M, Fiorentini G, Poddie D, Bertani M, Davitti B, Riitano G, Cavazzini G, Amigoni A, Guglielminetti D, Vaglini M, Smerieri F: Hypoxic abdominal perfusion (HAP): Rationale and evaluation of a new technique. Reg Cancer Treat 1995;8:64-66.
26. Zanon C, Goss M, Nicola F, Alabiso O, Zai S, Aymele AG, Castagneto B, Grosso M, Mancini A, Gazzera C, Pacitti A, Martina G, Vaj M, Mattalia A: Limits of aortic stop flow infusion chemotherapy in the treatment of advanced cancer. Panminerva Med 2001;43:243-248.
27. Klein ES, Berkenstadt H, Koller M, Papa MZ, Ben-Ari GY, Lieberman N, Perel A: Hemodynamic effects of aortic stop flow and total abdominal ischemic perfusion. Reg Cancer Treat 1994;2:82-85.
28. Eggermont AM, van IJken MG, van Etten B, van der Sijp JR, ten Hagen TL, Wiggers T, Oudkerk M, de Boeck G, de Bruijn EA: Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: From laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000;47:776-781.
29. Arredondo MA, Chaudhuri B, Kar R, Crist KA, Thomford NR, Chaudhuri PK: Isolated perfusion of pancreas with mitomycin C. Am J Surg 1990;159:569-574.
30. Guadagni S, Aigner KR, Palumbo G, Cantore M, Fiorentini G, Pozone T, Deraco M, Clerico M, Chaudhuri PK: Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: A pilot study of patients with recurrent unresectable rectal cancer. J Clin Pharmacol 1998;38:936-944.
31. Aigner KR, Gailhofer S, Kopp S: Regional versus systemic chemotherapy for advanced pancreatic cancer: A randomized study. Hepatogastroenterology 1998;45:1125-1129.
32. Klein ES, Ben-Ari GY, Papa MZ, Adar R, Bass A: Vascular complications of total abdominal perfusion and aortic stop flow-infusion. J Surg Oncol 1996;61:17-19.
33. Fiorentini G, Poddie D, Graziani G, Cantore M, Leoni M, Turci D, Dazzi C, Priori T, Tienghi A: Locoregional chemotherapy (LRC) with mitomycin C (MC) administered as intra-aortic stop-flow infusion (IASFI) with abdominal perfusion (HAP) in UICC stage III-IV pancreatic carcinoma (PC). Proceedings of ASCO 1997 (Annual Meeting), Chicago ASCO 1997, abstract No. 1024.